Login to Your Account

Regulatory NEWS

Even as they reached across the aisle to pat each other on the back in the lead-up to Wednesday's 392-26 House vote on the 21st Century Cures Act, several lawmakers signaled that the $6.3 billion bipartisan package is just the beginning of congressional action to increase funding for medical research, ensure the U.S. regulatory scene keeps up with medical advances and take steps to make drugs and devices more affordable.


In a week dotted with big news for the life science industries, the passage of 21st Century Cures legislation in the House of Representatives is perhaps the biggest. Investors and industry are understandably enthused at the development, but opponents, including Sen. Elizabeth Warren (D-Mass.), are blasting the legislation as a grab bag for industry that exposes patients to greater risk.

NEW DELHI – The Delhi High Court has set aside the Indian government's notification to ban 344 fixed-dose combination (FDC) medicines, which include some well-known branded cough syrups, saying the Indian government acted in a "haphazard manner."

More Regulatory Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: